Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Sees Large Increase in Short Interest

Key Points

• Short interest rose 134.8% to 580 shares as of October 15, up from 247 shares at the end of September. Despite the increase, short interest represented approximately 0.0% of outstanding shares, with a 0.3-day short-interest ratio.
• Molecular Partners shares gained 2.9% to $3.63, but remained below their 50-day and 200-day moving averages. The stock has traded between $3.51 and $5.36 over the past year.
• The company reported a quarterly loss of $0.38 per share, beating the consensus estimate of a $0.46 loss. Analyst sentiment is mixed, resulting in a consensus “Hold” rating and an average price target of $8.38.

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 580 shares, an increase of 134.8% from the September 30th total of 247 shares. Based on an average trading volume of 1,840 shares, the short-interest ratio is currently 0.3 days. Approximately 0.0% of the company's stock are sold short.

Molecular Partners Trading Up 2.9%

Shares of Molecular Partners stock traded up $0.10 during trading on Friday, hitting $3.63. 1,523 shares of the stock traded hands, compared to its average volume of 4,315. The stock's fifty day simple moving average is $4.05 and its 200 day simple moving average is $4.18. The firm has a market cap of $146.74 million, a P/E ratio of -2.13 and a beta of 1.11. Molecular Partners has a 52-week low of $3.51 and a 52-week high of $5.36.

Molecular Partners (NASDAQ:MOLN - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.08. As a group, equities analysts expect that Molecular Partners will post -1.28 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. HC Wainwright reissued a "buy" rating on shares of Molecular Partners in a report on Monday, July 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Molecular Partners in a report on Friday, October 2nd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Molecular Partners presently has a consensus rating of "Hold" and an average target price of $8.38.

About Molecular Partners

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland. The company develops therapeutic molecules based on its proprietary DARPin platform, which uses designed ankyrin repeat proteins to create targeted, multi-specific medicines intended to address complex disease pathways.

Molecular Partners' research and development activities have focused primarily on oncology, ophthalmology and infectious diseases. Its pipeline has included experimental programs designed to engage multiple biological targets, with the goal of improving treatment effectiveness and addressing limitations associated with conventional antibody-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.